Summary of single marker analyses in relation to cIMT.

<p>*Not in HWE.</p><p>**Adjusted by clinical variables: Age, Hypertension, Diabetes, Dyslipidemia and Antiretroviral Therapy.</p><p>Summary of single marker analyses in relation to cIMT.</p

Patients with VL >5.000 copies/ml (N = 55).

<p>Patients with VL >5.000 copies/ml (N = 55).</p

RAMS among patients with virological failure (VL>5.000 copies/ml) amplified and evaluated by genotyping.

<p>RAMS among patients with virological failure (VL>5.000 copies/ml) amplified and evaluated by genotyping.</p

Summary of single marker analyses in relation to atherosclerotic plaque presence.

<p>*maf: minor allele frequency/Aff: Affected/Unaff: Unaffected</p><p>**Adjusted by clinical variables: Age, Abdominal Obesity, Metabolic Syndrome, Hypertension, Diabetes, Dyslipidemia and Antiretroviral Therapy</p><p>Summary of single marker analyses in relation to atherosclerotic plaque presence.</p

Virological failure rates over time in different resource limited settings.

2<p> <b>Ferradini et al. Lancet 2006; 367:1335–42. ³ Ferradini et al. AIDS 2007, 21:2293–2301.</b></p

NNRTI's resistance mutations prevalence.

<p>NNRTI's resistance mutations prevalence.</p

Patient's disposition.

<p>Patient's disposition.</p

Patient cohort study profile.

<p>Patient cohort study profile.</p

Sensitivity, specificity, and predictive values of immunological and clinical criteria in identifying virological treatment failure.

<p>TP = true positive, FN = false negative, FP = false positive, TN = true negative.</p><p>Results are based in one CD4 and viral load result.</p

Kaplan Meier analysis from six months of therapy to clinical failure.

<p>Kaplan Meier analysis from six months of therapy to clinical failure.</p